REGENXBIO Inc. (RGNX): R&D Expense
$228.30M
Year ended 2025-12-31
$229.14M
Trailing 12 months to 2026-06-30
-2.0%
3-year compound annual growth
+6.5%
5-year compound annual growth
+29.4%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $228.30M | +9.5% | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | $208.52M | -10.2% | 2026-03-05, From 2024-01-01 |
| 2023-12-31 | $232.27M | -4.2% | 2025-03-13, From 2023-01-01 |
| 2022-12-31 | $242.45M | +33.6% | 2025-03-13, From 2022-01-01 |
| 2021-12-31 | $181.44M | +9.1% | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | $166.29M | +33.9% | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | $124.19M | +48.1% | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | $83.87M | +46.6% | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | $57.22M | +25.8% | 2020-02-26, From 2017-01-01 |
| 2016-12-31 | $45.48M | +163.2% | 2019-02-27, From 2016-01-01 |
| 2015-12-31 | $17.28M | +248.3% | 2018-03-06, From 2015-01-01 |
| 2014-12-31 | $4.96M | -1.8% | 2017-03-07, From 2014-01-01 |
| 2013-12-31 | $5.05M | n/a | 2016-03-03, From 2013-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | 2025-12-31 | $228.30M | +9.5% |
| Ginkgo Bioworks Holdings, Inc. (DNA) | 2025-12-31 | $243.77M | -42.5% |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | $149.06M | +17.8% |
| Beam Therapeutics Inc. (BEAM) | 2025-12-31 | $409.62M | +11.4% |
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $141.50M | +16.4% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $201.58M | +171.6% |
| Atara Biotherapeutics, Inc. (ATRA) | 2025-12-31 | $37.45M | -75.3% |
| Agenus Inc (AGEN) | 2025-12-31 | $79.34M | -49.0% |
| ImmunityBio, Inc. (IBRX) | 2024-12-31 | $190.14M | -18.2% |
Compare RGNX, DNA, ADAPY, BEAM side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗